143 related articles for article (PubMed ID: 17341147)
1. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Lekhanont K; Park CY; Smith JA; Combs JC; Preechawat P; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):27-34. PubMed ID: 17341147
[TBL] [Abstract][Full Text] [Related]
2. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
Lekhanont K; Leyngold IM; Suwan-Apichon O; Rangsin R; Chuck RS
Cornea; 2007 Jan; 26(1):84-9. PubMed ID: 17198019
[TBL] [Abstract][Full Text] [Related]
3. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
Lekhanont K; Park CY; Combs JC; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):83-8. PubMed ID: 17341156
[TBL] [Abstract][Full Text] [Related]
4. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Zhu L; Zhang C; Chuck RS
Mol Vis; 2012; 18():1803-12. PubMed ID: 22815633
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Suwan-apichon O; Rizen M; Rangsin R; Herretes S; Reyes JM; Lekhanont K; Chuck RS
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):133-9. PubMed ID: 16384954
[TBL] [Abstract][Full Text] [Related]
6. Effects of topical human amniotic fluid and human serum in a mouse model of keratoconjunctivitis sicca.
Quinto GG; Camacho W; Castro-Combs J; Li L; Martins SA; Wittmann P; Campos M; Behrens A
Cornea; 2012 Apr; 31(4):424-30. PubMed ID: 22290385
[TBL] [Abstract][Full Text] [Related]
7. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model.
Park CY; Zhuang W; Lekhanont K; Zhang C; Cano M; Lee WS; Gehlbach PL; Chuck RS
Mol Vis; 2007 Nov; 13():2222-32. PubMed ID: 18087241
[TBL] [Abstract][Full Text] [Related]
8. Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye.
Hongyok T; Chae JJ; Shin YJ; Na D; Li L; Chuck RS
Arch Ophthalmol; 2009 Apr; 127(4):525-32. PubMed ID: 19365035
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model.
Zhu L; Shen J; Zhang C; Park CY; Kohanim S; Yew M; Parker JS; Chuck RS
Mol Vis; 2009; 15():250-8. PubMed ID: 19190733
[TBL] [Abstract][Full Text] [Related]
10. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
Marsh P; Pflugfelder SC
Ophthalmology; 1999 Apr; 106(4):811-6. PubMed ID: 10201607
[TBL] [Abstract][Full Text] [Related]
11. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
12. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca.
Berdoulay A; English RV; Nadelstein B
Vet Ophthalmol; 2005; 8(4):225-32. PubMed ID: 16008701
[TBL] [Abstract][Full Text] [Related]
13. A mouse model of keratoconjunctivitis sicca.
Dursun D; Wang M; Monroy D; Li DQ; Lokeshwar BL; Stern ME; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):632-8. PubMed ID: 11867577
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic effects of Pyranoprofen on the mouse dry eye induced by topical medication of Benzalkonium Chloride].
He H; Liu ZG; Lin ZR; Liu XC; He H; Xiao QG
Zhonghua Yan Ke Za Zhi; 2012 Jan; 48(1):33-40. PubMed ID: 22490914
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.
Coassin M; Lambiase A; Costa N; De Gregorio A; Sgrulletta R; Sacchetti M; Aloe L; Bonini S
Graefes Arch Clin Exp Ophthalmol; 2005 Feb; 243(2):151-5. PubMed ID: 15650854
[TBL] [Abstract][Full Text] [Related]
16. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
Moore CP; McHugh JB; Thorne JG; Phillips TE
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
[TBL] [Abstract][Full Text] [Related]
19. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.
Morgan RV; Abrams KL
J Am Vet Med Assoc; 1991 Oct; 199(8):1043-6. PubMed ID: 1748607
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of topical infliximab in a mouse model of experimental dry eye.
Li Z; Choi W; Oh HJ; Yoon KC
Cornea; 2012 Nov; 31 Suppl 1():S25-31. PubMed ID: 23038030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]